Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)
NCT03493152 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2025-05-28
Summary
Single patient treatment with everolimus.
Conditions
- Gastrointestinal Stromal Tumor
Interventions
- DRUG
-
mTOR inhibitor
Sponsors & Collaborators
-
The University of Texas Health Science Center at San Antonio
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
NCT06462183 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Epacadostat and Pembrolizumab in Patients With GIST
NCT03291054 ·Status: TERMINATED ·Phase: PHASE2
-
Study for Patients Previously Treated in Avapritinib Clinical Trials
NCT04825574 ·Status: COMPLETED ·Phase: PHASE4
-
Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer
NCT00005076 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
NCT04148092 ·Status: APPROVED_FOR_MARKETING
-
The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium
NCT01801137 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
NCT03095781 ·Status: COMPLETED ·Phase: PHASE1
-
Pre-op Rectal ChemoRad +/- Cetuximab
NCT00527111 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
NCT01316263 ·Status: TERMINATED ·Phase: PHASE2
-
Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
NCT00677924 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
NCT00276302 ·Status: COMPLETED ·Phase: PHASE1
-
Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer
NCT07269249 ·Status: RECRUITING
-
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
NCT02110082 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
NCT01554969 ·Status: COMPLETED ·Phase: PHASE1
-
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
NCT03465722 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
NCT00309179 ·Status: COMPLETED ·Phase: PHASE2
-
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
NCT00083720 ·Status: COMPLETED ·Phase: PHASE2
-
Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
NCT00998751 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
NCT00754494 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
NCT00437268 ·Status: COMPLETED ·Phase: PHASE2
-
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
NCT00207155 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Immunotherapy in Colorectal Cancer
NCT05571293 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
NCT06087263 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
NCT00390364 ·Status: TERMINATED ·Phase: PHASE2